<DOC>
	<DOCNO>NCT01435031</DOCNO>
	<brief_summary>A prospective , multi-center , single-arm study establish safety effectiveness XIENCE V® Everolimus Eluting Coronary Stent , XIENCE nano™ Everolimus Eluting Coronary Stent , XIENCE PRIME™ LL Everolimus Eluting Coronary Stent , HT PROGRESS HT PILOT Coronary Guide Wires , MINI-TREK Coronary Dilatation Catheter patient undergo elective percutaneous revascularization native chronic total coronary occlusion</brief_summary>
	<brief_title>EXPERT CTO : Evaluation XIENCE PRIME™ LL XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents , Performance , Technique Chronic Total Occlusions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General 1 . Subject ≥ 18 year age time consent . 2 . Subject experience clinical symptom consider suggestive ischemic heart disease ( e.g. , chest pain discomfort , heart failure , etc . ) evidence myocardial ischemia ( e.g. , abnormal functional study ) attribute CTO target vessel schedule clinically indicate percutaneous revascularization . 3 . Subject eligible consent undergo percutaneous coronary intervention ( PCI procedure ) . 4 . Subject acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergency coronary artery bypass grafting ( CABG ) . 5 . Subject willing able sign inform consent form ( ICF ) approve local Institutional Review Board/Ethics Committee follow protocol 5year follow . 6 . Female subject childbearing potential must negative qualitative quantitative pregnancy test within 7 day enrollment effective birth control must use 1 year follow index procedure . Angiographic Inclusion Criteria 1 . A maximum one de novo lesion least one target segment native coronary vessel meeting definition chronic total occlusion . A `` chronic total occlusion '' nonacute total coronary occlusion fulfil follow angiographic characteristic estimate duration least 3 month clinical history and/or comparison antecedent angiogram electrocardiogram : Highgrade native coronary stenosis TIMI 0 1 antegrade flow 2 . Occluded segment suitable placement coronary stent : Segment without severe tortuosity ( angulation ≥ 45º ) Segment locate excessively distal location General Exclusion Criteria Candidates exclude study follow condition present : 1 . Patients history allergy iodinate contrast effectively manage medically , know allergy clopidogrel bisulfate ( Plavix® ) , aspirin , heparin , stainless steel , everolimus 2 . Evidence acute myocardial infarction ( MI ) within 72 hour intend treatment ( define : Qwave nonQwave MI creatine kinase ( CK ) enzymes 2 × upper limit normal ( ULN ) presence creatine kinase myocardialband isoenzyme ( CKMB ) Institution 's ULN , troponin ( I T ) Institution 's ULN ) 3 . Previous coronary interventional procedure kind within 30 day prior procedure target vessel 4 . Planned interventional treatment either target nontarget vessel within 30 day postprocedure 5 . Planned interventional treatment either target nontarget vessel within 6 month postprocedure alternative drug elute stent ( DES ) ( e.g. , CYPHER SirolimusEluting stent , TAXUS PaclitaxelEluting stent Endeavor ZotarolimusEluting Endeavor stent ) 6 . Any contraindication cardiac catheterization standard concomitant therapy use routine cardiac catheterization PCI ( e.g. , aspirin , clopidogrel , unfractionated heparin ) 7 . Target lesion require treatment device successful crossing PTCA prior stent placement ( include , limited directional rotational coronary atherectomy , excimer laser , thrombectomy , etc. ) . Note : Use alternative technology conventional guide wire approve United States Food Drug Administration CTO revascularization ( e.g. , Asahi Tornus Corsair catheter , IntraLuminal Therapeutics Safe Cross guide wire , Flowcardia CROSSER system ) permit collected case report form . 8 . Patients history clinically significant abnormal laboratory finding include : Neutropenia ( &lt; 1000 neutrophils/mm3 ) within previous 2 week , Thrombocytopenia ( &lt; 100,000 platelets/mm3 ) , Aspartate Transaminase ( AST ) , Alanine Aminotransferase ( ALT ) , alkaline phosphatase , bilirubin &gt; 1.5 × ULN , Serum creatinine &gt; 1.5 mg/dL 9 . Patients evidence ongoing active clinical instability include follow : Sustained systolic blood pressure &lt; 100 mmHg cardiogenic shock Acute pulmonary edema severe congestive heart failure Suspected acute myocarditis , pericarditis , endocarditis , cardiac tamponade Suspected dissect aortic aneurysm Hemodynamically significant valvular heart disease , hypertrophic cardiomyopathy , restrictive cardiomyopathy , congenital heart disease 10 . Target lesion involve bifurcation include diseased side branch ≥2.25 mm diameter would require treatment 11 . Target vessel patent bypass graft prior coronary bypass surgery 12 . Proximal coronary stenting target lesion 13 . History stroke transient ischemic attack within prior 6 month 14 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month 15 . History bleed diathesis coagulopathy refusal blood transfusion 16 . Patients pathology cancer , mental illness , etc. , opinion Investigator , might put patient risk , preclude followup , way confound result study . 17 . Known previous medical condition yielding expect survival less 1 year . 18 . Patients unable unwilling comply protocol expect complete study period , include followup requirement . 19 . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint ; require coronary angiography , intravascular ultrasound ( IVUS ) , coronary artery imaging procedure Angiographic Exclusion Criteria Candidates exclude study follow condition meet : 1 . Occlusion involve segment within previous stent 2 . Extensive lesionrelated thrombus ( TIMI thrombus grade 3 4 ) 3 . Previous stenting ( drugeluting bare metal ) target vessel unless follow condition meet : It least 9 month since previous stenting . That target lesion least 15 mm away previously place stent . The previously stented segment ( stent plus 5 mm either side ) 40 % diameter stenosis . 4 . The target vessel lesion proximal total occlusion identify great 40 % diameter stenosis base visual estimate online quantitative coronary angiography ( QCA ) . However , plan stenting lesion target vessel proximal target lesion cover single stent ( ie , tandem lesion ) acceptable . Exclusion Criteria ( Nontarget Lesion ) : 1 . The lesion locate native vessel distal anastomosis graft . 2 . The vessel lesion great 40 % diameter stenosis base visual estimate online QCA . 3 . The vessel evidence thrombus . 4 . The vessel excessively tortuous . 5 . The lesion follow characteristic : Lesion location aortoostial , unprotected leave main lesion , within 5 mm origin leave anterior descend coronary artery ( LAD ) , leave circumflex coronary artery ( LCX ) , right coronary artery ( RCA ) . Involves side branch &gt; 2.0 mm diameter . Is distal &gt; 45º bend vessel . Is moderately severely calcify . TIMI flow 0 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Chronic Total Occlusion ( CTO )</keyword>
	<keyword>Chronic total coronary occlusion</keyword>
	<keyword>Coronary Artery Disease ( CAD )</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Total coronary occlusion</keyword>
</DOC>